Rheumatoid Arthritis- ARG301


Rheumatoid arthritis is a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Unlike the wear-and-tear damage of osteoarthritis, rheumatoid arthritis affects the lining of your joints, causing a painful swelling that can eventually result in bone erosion and joint deformity.


An autoimmune disorder, rheumatoid arthritis occurs when your immune system mistakenly attacks your own body's tissues. In addition to causing joint problems, rheumatoid arthritis sometimes can affect other organs of the body — such as the skin, eyes, lungs and blood vessels.


Although rheumatoid arthritis can occur at any age, it usually begins after age 40. The disorder is much more common in women than in men. Treatment focuses on controlling symptoms and preventing joint damage.


arGentis' treatment, ARG301, utilized a modified peptide ligand to treat the disease.  The first in man, Phase I clinical trail, is currently being conducted with results expected in 2015.  There are patents pending in the US and EU.

arGentis
Pharmaceuticals, LLC

Aut​oImmune Disease Treatments